HomeCompareNBRI vs JNJ

NBRI vs JNJ: Dividend Comparison 2026

NBRI yields 333333.33% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NBRI wins by $8.099219044190773e+31M in total portfolio value
10 years
NBRI
NBRI
● Live price
333333.33%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.099219044190773e+31M
Annual income
$80,944,421,463,343,720,000,000,000,000,000,000,000.00
Full NBRI calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — NBRI vs JNJ

📍 NBRI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNBRIJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NBRI + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NBRI pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NBRI
Annual income on $10K today (after 15% tax)
$28,333,333.33/yr
After 10yr DRIP, annual income (after tax)
$68,802,758,243,842,160,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, NBRI beats the other by $68,802,758,243,842,160,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NBRI + JNJ for your $10,000?

NBRI: 50%JNJ: 50%
100% JNJ50/50100% NBRI
Portfolio after 10yr
$4.0496095220953863e+31M
Annual income
$40,472,210,731,671,860,000,000,000,000,000,000,000.00/yr
Blended yield
99.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

NBRI
No analyst data
Altman Z
-38.0
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NBRI buys
0
JNJ buys
0
No recent congressional trades found for NBRI or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNBRIJNJ
Forward yield333333.33%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$8.099219044190773e+31M$30.3K
Annual income after 10y$80,944,421,463,343,720,000,000,000,000,000,000,000.00$4,689.40
Total dividends collected$8.098906375781879e+31M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NBRI vs JNJ ($10,000, DRIP)

YearNBRI PortfolioNBRI Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$33,344,033$33,333,333.33$10,592$272.30+$33.33MNBRI
2$103,911,171,366$103,875,493,250.26$11,289$357.73+$103911.16MNBRI
3$302,644,656,190,810$302,533,471,237,448.00$12,123$472.89+$302644656.18MNBRI
4$823,817,797,451,856,400$823,493,967,669,732,100.00$13,141$629.86+$823817797451.84MNBRI
5$2,095,836,995,961,804,000,000$2,094,955,510,918,530,000,000.00$14,408$846.81+$2095836995961804.00MNBRI
6$4,983,251,920,823,462,000,000,000$4,981,009,375,237,783,000,000,000.00$16,021$1,151.60+$4983251920823461888.00MNBRI
7$11,073,835,968,753,321,000,000,000,000$11,068,503,889,198,040,000,000,000,000.00$18,122$1,588.22+$1.1073835968753322e+22MNBRI
8$22,999,277,308,531,336,000,000,000,000,000$22,987,428,304,044,770,000,000,000,000,000.00$20,930$2,228.20+$2.2999277308531335e+25MNBRI
9$44,643,905,199,991,210,000,000,000,000,000,000$44,619,295,973,271,085,000,000,000,000,000,000.00$24,792$3,191.91+$4.464390519999121e+28MNBRI
10$80,992,190,441,907,720,000,000,000,000,000,000,000$80,944,421,463,343,720,000,000,000,000,000,000,000.00$30,274$4,689.40+$8.099219044190773e+31MNBRI

NBRI vs JNJ: Complete Analysis 2026

NBRIStock

North Bay Resources Inc. operates as a natural resources exploration company in North America. The company explores for gold, silver, copper, platinum, palladium, rhodium, iridium, osmium, and wollastonite deposits, as well as vanadium, crystalline flake graphite, and rare earth elements. It holds 100% interest in the Mount Washington project located in Vancouver Island; and the Tulameen platinum project located in Princeton in the British Columbia. The company also holds interests in the Zeballos Gold property, which covers an area of 1,017 hectares located in Vancouver Island; the Fraser River Platinum property that covers an area of 413 hectares situated in Lytton, British Columbia; and the Zippa Mountain Wollastonite property, which covers an area of 2,456 hectares located in Smithers, British Columbia. North Bay Resources Inc. was incorporated in 2004 and is based in Collegeville, Pennsylvania.

Full NBRI Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this NBRI vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NBRI vs SCHDNBRI vs JEPINBRI vs ONBRI vs KONBRI vs MAINNBRI vs ABBVNBRI vs MRKNBRI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.